Invivyd, Inc. (IVVD)

Market Cap	131.25M
Revenue (ttm)	n/a
Net Income (ttm)	-206.82M
Shares Out	119.32M
EPS (ttm)	-1.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	310,075
Open	1.170
Previous Close	1.200
Day's Range	1.100 - 1.200
52-Week Range	1.080 - 5.195
Beta	0.79
Analysts	Strong Buy
Price Target	9.50 (+763.64%)
Earnings Date	Aug 8, 2024

About IVVD

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in precl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 94
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD

Analyst Forecast

According to 4 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 763.64% from the latest price.

Price Target

$9.5

(763.64% upside)

Analyst Consensus: Strong Buy